Skybiotech Healthcare Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended 31st March, 2026, in accordance with SEBI (Depositories and Participants) Regulations, 2018. The company, formerly known as Kapil Cotex Limited, submitted the mandatory documentation on 09th April, 2026.

Regulatory Compliance Certificate

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which requires companies to report on the dematerialization of physical share certificates. Satellite Corporate Services Pvt. Ltd., serving as the company's Registrar and Share Transfer Agent, provided the compliance certificate dated 06th April, 2026.

Dematerialization Status

The certificate confirms that no physical share certificates were received for dematerialization during the quarter ended 31st March, 2026. This indicates that all existing shares of the company remain in their current form without any conversion from physical to electronic format during the reporting period.

Satellite Corporate Services Pvt. Ltd., a Category-I Registrar with registration number INR000003639, certified that the standard verification processes for dematerialization were maintained, though no physical certificates required processing during Q4 FY26.

Company Information

Skybiotech Healthcare Limited operates under CIN L21001MH1983PLC031114 with its registered office located at Gut No. 05, Gevrai Tanda, Paithan Road, Chh. Sambhaji Nagar (Aurangabad), Maharashtra. The filing was signed by Managing Director Poonam Prakash Rathi (DIN: 01274428), ensuring proper authorization of the regulatory submission.

This compliance filing represents the company's ongoing commitment to meeting SEBI's regulatory requirements for listed entities and maintaining transparency in share transfer operations.

Skybiotech Healthcare Limited has released its unaudited financial results for the quarter ended December 31, 2025, marking another reporting milestone following its recent corporate transformation. The company, formerly known as Kapil Cotex Limited, conducted its board meeting on February 14, 2026, to review and approve the quarterly financial statements.

Board Meeting and Financial Approval

The Board of Directors convened on Saturday, February 14, 2026, from 5:00 PM to 6:30 PM to consider and approve the unaudited financial results for both standalone and consolidated operations. The meeting was conducted in compliance with Regulation 30(6) and 30(2) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The Audit Committee reviewed and recommended the financial results before the Board's final approval. The statutory auditors have issued a Limited Review Report, which has been taken on record by the Board.

Corporate Name Change Details

A significant corporate development occurred during the reporting period, with the company officially changing its name from Kapil Cotex Limited to Skybiotech Healthcare Limited. The name change process involved several key dates:

Earnings Per Share Information

The financial results include earnings per share data for continuing operations. The basic earnings per share figures show values of -0.30, 6.79, -1.03, 0.15, 7.56, and -1.50 across different periods. Similarly, the diluted earnings per share reflects the same values for continuing operations, while no earnings per share were reported for discontinuing operations during the periods under review.

Operational Structure and Compliance

The company operates as a single-segment business, with all operations relating to one primary segment. This structure means that segment reporting as defined in Accounting Standard 17 is not applicable to the company's financial reporting requirements.

The financial results have been prepared in accordance with SEBI regulations, with previous period figures regrouped where necessary for better comparability and presentation.

Company Information

Skybiotech Healthcare Limited maintains its registered office at Gut No. 05, Gevrai Tanda, Paithan Road, Chhatrapati Sambhaji Nagar (Aurangabad), Maharashtra 431002. The company continues to trade on BSE under script code 512036, with Poonam Prakash Rathi serving as Managing Director (DIN: 01274428).